Other CAF-targeting drugs that are currently under clinical trials may also be repurposed for the treatment of recurrent HNSCC, including inhibitors of FAK (PTK2), ROCK, and CXCR4 which we have found to be significantly overexpressed and/or hyper-activated in the recurrent tumors. The gene discussed is PTK2; the disease is head and neck squamous cell carcinoma.